

AMENDMENTS TO THE SPECIFICATION

Please replace paragraph [085] with the following rewritten paragraph:

[085] Next, pMDLg/p was generated, which is a CMV-driven packaging construct that contains only the *gag* and *pol* coding sequences from HIV-1. First, pkat2Lg/p was constructed by ligating a 4.2-kb ClaI-EcoRI fragment from pCMVR8.74 with a 3.3-kb EcoRI-HindIII fragment from pkat2, Finer et al., *Blood* 83:43-50 (1994), and a 0.9-kb HindIII-NcoI fragment from pkat2 along with an NcoI-ClaI linker consisting of synthetic oligonucleotides 5'-CATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGAT-3' (SEQ ID NO: 1) and 5'-CGATCTAATTCTCCCCCGCTTAATACTGACGCTCTCGCACC-3' (SEQ ID NO: 2). pCMVR8.74 is a derivative of pCMVR8.91, described above, in which a 133-bp SacII fragment, containing a splice donor site, has been deleted from the CMV-derived region upstream of the HIV sequences to optimize expression. Second, pMDLg/p was constructed by inserting the 4.25-kb EcoRI fragment from pkat2Lg/p into the EcoRI site of pMD-2. pMD-2 is a derivative of pMD.G, Ory et al., *Proc. Natl. Acad. Sci. USA*, 93:11400-406 (1996), in which the pXF3 plasmid backbone of pMD.G has been replaced with a minimal pUC plasmid backbone and the 1.6-kb VSV G-encoding EcoRI fragment has been removed.

Please replace paragraph [086] with the following rewritten paragraph:

[086] Finally, packaging construct pMDLg/pRRE was produced, which differs from pMDLg/p by the addition of a 374-bp RRE-containing sequence from HIV-1 (HXB2) immediately downstream of the *pol* coding sequences. To generate pMDLg/pRRE, the 374-bp NotI-HindIII RRE-containing fragment from pHR3 was ligated into the 9.3-kb NotI-BglII fragment of pVL1393 (Invitrogen, San Diego, Calif.) along with a HindIII-BglII oligonucleotide linker consisting of synthetic oligonucleotides 5'-AGCTTCCGCGGA-3' (SEQ ID NO: 3) and 5'-GATCTCCGCGGA-3' (SEQ ID NO: 4) to generate pVL1393RRE (pHR3 was derived from pHR2 by the removal of HIV *env* coding sequences upstream of the RRE sequences in pHR2, where pHR2 is a transducing vector described below in Example II). A NotI site remains at the junction between the *gag* and RRE sequences. pMDLg/pRRE was then constructed by ligating the 380-bp EcoRI-SstII fragment from pVL1393RRE with the 3.15-kb SstII-NdeI fragment from pMD-2FIX (pMD-2FIX is a human factor IX-containing variant of pMD-2 which has an SstII site at the 3' end of the factor IX insert), the 2.25-kb